306 related articles for article (PubMed ID: 31085720)
21. T cells specific for α-myosin drive immunotherapy-related myocarditis.
Axelrod ML; Meijers WC; Screever EM; Qin J; Carroll MG; Sun X; Tannous E; Zhang Y; Sugiura A; Taylor BC; Hanna A; Zhang S; Amancherla K; Tai W; Wright JJ; Wei SC; Opalenik SR; Toren AL; Rathmell JC; Ferrell PB; Phillips EJ; Mallal S; Johnson DB; Allison JP; Moslehi JJ; Balko JM
Nature; 2022 Nov; 611(7937):818-826. PubMed ID: 36385524
[TBL] [Abstract][Full Text] [Related]
22. Role of Biomarkers in the Management of Immune-Checkpoint Inhibitor-Related Myocarditis.
Vasbinder A; Ismail A; Salem JE; Hayek SS
Curr Cardiol Rep; 2023 Sep; 25(9):959-967. PubMed ID: 37436648
[TBL] [Abstract][Full Text] [Related]
23. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
[TBL] [Abstract][Full Text] [Related]
25. Management of immune-related adverse events resulting from immune checkpoint blockade.
Baroudjian B; Arangalage D; Cuzzubbo S; Hervier B; Lebbé C; Lorillon G; Tazi A; Zalcman G; Bouattour M; Lioté F; Gautier JF; Brosseau S; Lourenco N; Delyon J;
Expert Rev Anticancer Ther; 2019 Mar; 19(3):209-222. PubMed ID: 30572735
[TBL] [Abstract][Full Text] [Related]
26. Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
Ma P; Liu J; Qin J; Lai L; Heo GS; Luehmann H; Sultan D; Bredemeyer A; Bajapa G; Feng G; Jimenez J; Parks A; Amrute J; Villanueva A; Liu Y; Lin CY; Mack M; Amancherla K; Moslehi J; Lavine KJ
bioRxiv; 2023 Apr; ():. PubMed ID: 37162929
[TBL] [Abstract][Full Text] [Related]
27. Subclinical Myocarditis After Combination Immune Checkpoint Inhibitor Therapy.
Giblin GT; Dennehy C; Featherstone H; Clarke R; Murphy L; Timlin D; O'Keane C; Mulligan N; Kelly CM; Joyce E
Circ Heart Fail; 2021 Feb; 14(2):e007524. PubMed ID: 33478241
[No Abstract] [Full Text] [Related]
28. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
[TBL] [Abstract][Full Text] [Related]
29. TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis.
Liu X; Wu W; Fang L; Liu Y; Chen W
Front Immunol; 2022; 13():922782. PubMed ID: 35844550
[TBL] [Abstract][Full Text] [Related]
30. Immune Checkpoint Inhibitor-Associated Myocarditis.
Ganatra S; Neilan TG
Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
[TBL] [Abstract][Full Text] [Related]
31. Protective effect of low-intensity pulsed ultrasound on immune checkpoint inhibitor-related myocarditis via fine-tuning CD4
Fu S; Guo Z; Xu X; Li Y; Choi S; Zhao P; Shen W; Gao F; Wang C; Chen S; Li Y; Tian J; Sun P
Cancer Immunol Immunother; 2024 Jan; 73(1):15. PubMed ID: 38236243
[TBL] [Abstract][Full Text] [Related]
32. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
[TBL] [Abstract][Full Text] [Related]
33. Immune checkpoint inhibitors myocarditis: not all cases are clinically patent.
Thibault C; Vano Y; Soulat G; Mirabel M
Eur Heart J; 2018 Oct; 39(38):3553. PubMed ID: 30107497
[No Abstract] [Full Text] [Related]
34. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
35. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.
Chen Q; Huang DS; Zhang LW; Li YQ; Wang HW; Liu HB
Clin Toxicol (Phila); 2018 Jul; 56(7):667-671. PubMed ID: 29126352
[TBL] [Abstract][Full Text] [Related]
36. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
[TBL] [Abstract][Full Text] [Related]
37. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
Michel L; Totzeck M; Lehmann L; Finke D
Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
[TBL] [Abstract][Full Text] [Related]
38. Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis.
Shindo A; Yamasaki M; Uchino K; Yamasaki M
Int Heart J; 2022; 63(1):180-183. PubMed ID: 35095069
[TBL] [Abstract][Full Text] [Related]
39. Management of immune related adverse events induced by immune checkpoint inhibition.
Teufel A; Zhan T; Härtel N; Bornschein J; Ebert MP; Schulte N
Cancer Lett; 2019 Aug; 456():80-87. PubMed ID: 31051213
[TBL] [Abstract][Full Text] [Related]
40. Cardiac Complications in Immune Checkpoint Inhibition Therapy.
Tajiri K; Ieda M
Front Cardiovasc Med; 2019; 6():3. PubMed ID: 30729114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
